Home » Topics » BioWorld Science

BioWorld Science
RSS

IDMC recommends continuation of enrollment in phase IIa study of milciclib in HCC

May 17, 2018

Eiger Biopharmaceuticals obtains rights to lonafarnib for Hutchinson-Gilford progeria syndrome

May 17, 2018

KalVista Pharmaceuticals develops new agents for diabetic retinopathy

May 17, 2018

First phase III clinical results presented for esketamine in treatment-resistant depression

May 17, 2018

FluGen's M2SR influenza vaccine begins challenge study

May 17, 2018

FDA grants rare pediatric disease designation to MYO-101 for limb girdle muscular dystrophy type 2E

May 17, 2018

FDA awards rare pediatric disease designation to CCP-020

May 17, 2018

Flash Therapeutics created from Vectalys and FlashCell merger

May 17, 2018

Emulate and AstraZeneca enter Organs-on-Chips technology agreement

May 17, 2018

FDA accepts Turnstone Biologics' IND for MG1-HPV

May 17, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...